Fideuram Asset Management Ireland dac Takes $639,000 Position in Cencora, Inc. $COR

Fideuram Asset Management Ireland dac bought a new stake in Cencora, Inc. (NYSE:COR) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,892 shares of the company’s stock, valued at approximately $639,000.

Several other institutional investors have also modified their holdings of the stock. Principia Wealth Advisory LLC grew its position in shares of Cencora by 3,462.5% in the fourth quarter. Principia Wealth Advisory LLC now owns 285 shares of the company’s stock valued at $96,000 after purchasing an additional 277 shares during the period. National Pension Service boosted its position in Cencora by 6.3% during the fourth quarter. National Pension Service now owns 720,381 shares of the company’s stock worth $243,309,000 after acquiring an additional 42,652 shares during the last quarter. Basepoint Wealth LLC acquired a new position in Cencora during the fourth quarter worth about $32,000. Northwestern Mutual Wealth Management Co. boosted its position in Cencora by 27.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 28,324 shares of the company’s stock worth $9,566,000 after acquiring an additional 6,087 shares during the last quarter. Finally, Ilmarinen Mutual Pension Insurance Co acquired a new position in Cencora during the fourth quarter worth about $2,871,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Performance

NYSE:COR opened at $269.21 on Friday. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The firm has a market capitalization of $52.38 billion, a price-to-earnings ratio of 20.65, a PEG ratio of 1.24 and a beta of 0.64. The company’s 50-day moving average is $298.56 and its two-hundred day moving average is $333.91. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Analysts forecast that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.9%. The ex-dividend date is Friday, May 15th. Cencora’s payout ratio is presently 18.40%.

Cencora declared that its board has authorized a stock repurchase plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to purchase up to 3.9% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Citigroup lowered their price target on shares of Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Leerink Partners restated an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Wells Fargo & Company lowered their price target on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research report on Monday, May 11th. Robert W. Baird lowered their price target on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Finally, Morgan Stanley set a $342.00 price target on shares of Cencora in a research report on Friday, May 8th. Twelve investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $380.25.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.